Market Overview

Argus Gives Medtronic Improved Prognosis, Expects Nearly 10% Future Growth

Share:
Argus Gives Medtronic Improved Prognosis, Expects Nearly 10% Future Growth
Related MDT
Jim Cramer Advises His Viewers On Cisco, Microsoft And More
10 Biggest Price Target Changes For Monday
Axonics Modulation Technologies Proposes Terms For $100 Million IPO (Seeking Alpha)

Medtronic PLC (NYSE: MDT) is poised for better opportunities ahead after a long period of underperformance, Argus said in a Tuesday note.

The firm noted that shares of Medtronic have underperformed the broader market over the past three months, adding 1.9 percent compared to the S&P 500's 6.7-percent advance. Over the past year, Medtronic is 12.9 percent higher, underperforming the S&P 500's 17.3-percent gain.

The Analyst

Argus analyst John Eade upgraded shares of Medtronic from Hold to Buywith a $95 price target.

The Thesis

Medtronic has generated cost synergies from the Covidien Ltd (NYSE: COV) acquisition and is now seeking to boost operating margins, Eade said. (See Eade's track record here.)

Medtronic is integrating tuck-in acquisitions completed in fiscal year 2017, the analyst said. 

Argus estimates Medtronic's growth will reach 10 percent over the next two years. The company has cut down its debt using proceeds from asset sales, Eade said. 

Medtronic shares trade at a discount to the peer group. Argus' $95 price target assumes valuation multiples closer to industry averages. Additionally, Eade said Argus likes the stock's 2.3-percent dividend yield and the management's focus on shareholder returns.

"We think the MDT shares are attractively valued at current prices near $81. The shares are trading above the midpoint of the 52-week range of $69-$89," the analyst said. 

"From a technical standpoint, the stock appears to be in a bullish pattern of higher highs and higher lows that began in late September."

The Price Action

Medtronic shares are up over 15 percent year-to-date.

Medtronic was up less than 1 percent at $82.08 at the time of publication.

Related Links:

Cowen: Hologic Is A Relatively Cheap Stock Overdue For Upside

FDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health

Photo courtesy of Medtronic. 

Latest Ratings for MDT

DateFirmActionFromTo
Oct 2018BarclaysInitiates Coverage OnOverweight
Oct 2018ArgusMaintainsBuyBuy
Aug 2018ArgusMaintainsBuyBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Argus John EadeAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (COV + MDT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TEAMKeyBancUpgrades89.0
VIABImperial CapitalUpgrades29.0
AMDBarclaysUpgrades25.0
CDNSJP MorganUpgrades51.0
EBAYRBC CapitalDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

What's Up With Nvidia?

8 Stocks To Play The 'Star Wars: The Last Jedi' Release